Bicyclic heterocycles as FGFR4 inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9890156
APP PUB NO 20160244448A1
SERIAL NO

15047876

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INCYTE HOLDINGS CORPORATION1801 AUGUSTINE CUT-OFF WILIMINGTON DE 19803
INCYTE CORPORATION1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Lu, Liang Hockessin, US 118 2257
Qian, Ding-Quan Newark, US 87 2484
Wu, Liangxing Wilmington, US 162 5431
Yao, Wenqing Chadds Ford, US 324 9447

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 13, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 13, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00